CAR T therapy shows durable responses in large B-cell lymphoma

Wistar scientists uncover new viral mechanism for evading immunity, identifying a new drug target

Researchers at The Wistar Institute have identified a previously unknown mechanism by which viruses can reprogram mitochondrial structure to silence immune responses and ensure successful viral reproduction.

May 23, 2025

Vol.51 No.20

In Brief

Intermountain Health to expand stem cell collection for CAR-T cell therapy, bringing procedure to southern Utah

Intermountain Health is now offering a national expansion of CAR-T cell therapy, bringing cancer care closer to patients in southern Utah and Nevada.

May 16, 2025

Vol.51 No.19

In Brief

OncoHost awarded €2.5M grant from the EIC Transition Programme to advance precision oncology

OncoHost, together with its partners Heidelberg University Hospital, European Institute of Oncology and Virgen Macarena University Hospital, announced on May 15 that the parties have been awarded a €2.5 million grant from the EIC Transition Program of Horizon Europe.

May 16, 2025

Vol.51 No.19

Drugs & Targets

RyboDyn expands strategic cancer immunotherapy collaboration with Moffitt Cancer Center

RyboDyn, Inc. announced on May 15 the expansion of its strategic collaboration with Moffitt Cancer Center, a global leader in cancer care and research.

May 16, 2025

Vol.51 No.19

Rewriting the rules of cancer treatment one nanobody at a time

I joined Translational Genomics Research Institute, part of City of Hope, late last year to launch the Center for Accelerated Nanotherapeutics.

EU approves Calquence + chemo as first and only BTK inhibitor for first-line MLC

The European Medicines Agency approved Calquence (acalabrutinib) in combination with bendamustine and rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma who are not eligible for autologous stem cell transplant.

May 09, 2025

Vol.51 No.18

CAR T therapy shows durable responses in large B-cell lymphoma

YOU MAY BE INTERESTED IN

Wistar scientists uncover new viral mechanism for evading immunity, identifying a new drug target

Intermountain Health to expand stem cell collection for CAR-T cell therapy, bringing procedure to southern Utah

OncoHost awarded €2.5M grant from the EIC Transition Programme to advance precision oncology

RyboDyn expands strategic cancer immunotherapy collaboration with Moffitt Cancer Center

Rewriting the rules of cancer treatment one nanobody at a time

EU approves Calquence + chemo as first and only BTK inhibitor for first-line MLC

Renew today!

Subscriber content

Never miss an issue!

Login